Daiichi Sankyo and AstraZeneca Win CHMP Backing for Enhertu in HER2-Positive Breast Cancer
Tokyo, July 24, 2026 Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for...
pertuzumab
Advertisement
Pfizer Expands IBRANCE Label with New FDA Approval for HER2+ Breast Cancer
NEW YORK, June 24, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE®...
Pfizer’s TUKYSA Shows Strong Benefit in First-Line HER2+ Breast Cancer
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...
Advertisement
